Aerosolized or Irrigated Anti-infectives for Sinusitis
Customize your policy alerts
Sign up for Aetna Policy 0593 alerts
Get alerted when Policy 0593 changes without checking for updates manually.
Monitor payer policy activity
This policy governs the use and coverage stance for nasally aerosolized or irrigated anti-infective therapies for sinusitis for Aetna members.
No material clinical or coverage changes in this revision.
Coverage Determinations
Experimental/Investigational
Covered when ALL of the following are met:
Policy states lack of guideline support and limited data; use outside clearly established indications (e.g., cystic fibrosis or Pneumocystis pneumonia) should be exercised with caution.
This Clinical Policy Bulletin addresses the use of nasally aerosolized or irrigated anti-infectives for sinusitis. Professional guidance does not support routine use of these therapies for sinusitis, and the policy notes that such administration is considered experimental and investigational for treatment of sinusitis. Established indications for aerosolized antimicrobials — for example, treatment in patients with cystic fibrosis or Pneumocystis pneumonia — exist in other clinical contexts and are distinct from the sinusitis indication described here. Requests to use nasally aerosolized or irrigated anti-infectives for sinusitis fall outside those established indications and are subject to the policy’s investigational determination.
Randomized, placebo-controlled trials have not demonstrated convincing clinical benefit from adding nebulized or nasally irrigated antibiotics to saline or placebo in sinusitis. A randomized study by Desrosiers et al (2001) in 20 patients with chronic, refractory sinusitis found no clinically significant difference between nebulized tobramycin-saline solution and nebulized saline, leading the authors to conclude that the addition of tobramycin appears to be of minimal benefit.
A small randomized, double-blind, placebo-controlled crossover pilot study by Videler et al (2008) in 14 patients with recalcitrant chronic rhinosinusitis reported improvement in symptoms in both antibiotic and placebo (saline) arms, with no significant difference between bacitracin/colimycin and placebo. The investigators noted these small placebo-controlled studies consistently point to no effect from adding topical antibiotics and emphasized the need for larger randomized trials to draw definitive conclusions.
Coding and Billing
| J01.00-J01.91 | Acute sinusitis. |
| J32.0-J32.9 | Chronic sinusitis. |
Provider Responsibilities and Operational Guidance
Experimental/Investigational — denial risk
Aetna considers nasally aerosolized or irrigated anti-infectives experimental and investigational for the treatment of sinusitis due to inadequate published clinical evidence of effectiveness. Requests to treat sinusitis with these approaches are at risk of denial.
- Affected diagnoses: ICD-10 J01.00–J01.91 (Acute sinusitis); J32.0–J32.9 (Chronic sinusitis).
- Related policy: CPB 0065 - Nebulizers.
Prior authorization — verify with payer
There are no specific prior authorization instructions provided in the referenced policy text. Providers should verify member-specific benefit coverage and any plan-level prior authorization requirements through the payer's standard authorization channels before initiating treatment.
Therapy sequencing — conservative treatments first
Conservative therapies such as physiologic saline nasal irrigation and intranasal steroids (for CRS with polyposis) are supported by the literature; topical antimicrobials have limited/low-level evidence and should be considered only after standard therapies and culture-directed approaches when clinically appropriate.
- Physiologic saline irrigation: supportive evidence for symptom relief.
- Topical antibiotics: low-level evidence; culture-directed therapy preferred.
Evidence limitations — documentation suggestions
Published studies are limited in size and quality (many uncontrolled, retrospective, or small randomized trials). Detailed clinical documentation should include indication, prior conservative treatments tried, culture results if topical antibiotics are considered, treatment regimen, and outcome measures.
- Document prior systemic and topical therapies and duration.
- Include culture-directed organism and sensitivity when topical antibiotics are used.
- Record objective and patient-reported outcomes and duration of therapy.
Provider responsibility — plan-level guidance only
This policy summary is a plan-level coverage determination. Treating providers are responsible for all medical advice, diagnosis, and treatment decisions. The Clinical Policy Bulletin is informational and does not replace individualized clinical judgment.
Background and Rationale
Nebulized and nasally irrigated anti-infectives have been proposed to deliver antibiotics or antifungals directly to the sinus mucosa to improve local concentrations and reduce systemic exposure. Proprietary devices and formulations such as the SinuNEB system and AdhesENT formulations are marketed to enhance deposition and medication adherence within the sinus cavities and claim improved effectiveness compared with systemic administration.
Published clinical evidence for these approaches is limited and consists mainly of uncontrolled case series, retrospective reviews, and small randomized trials. Manufacturer‑reported uncontrolled series suggested subjective improvement in some patients, but prospective randomized trials have not demonstrated consistent benefit. Leading professional guidelines do not recommend a role for nebulized or nasally irrigated antibiotics in routine sinusitis management, and the literature cautions that data are insufficient to support routine use outside clearly established indications (e.g., cystic fibrosis, Pneumocystis).
Because available studies are small and often nonrandomized, no firm conclusions about safety or effectiveness can be drawn for routine treatment of sinusitis with nebulized or nasally irrigated anti-infectives.
Definitions and Devices
Policy Dates and History
Clinical policy last reviewed on 2023-09-07 per document metadata.
Next scheduled policy review date is 2024-06-27 per document metadata.
Policy originally became effective on 2002-03-08.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.